ESTRO 2024 - Abstract Book

S685

Clinical - Breast

ESTRO 2024

2837

Poster Discussion

Metabolic profiling of plasma and tissue in breast cancer patients: uncovering therapeutic response

Andrea Jiménez-Franco 1 , David Calderón 2 , Juanma Jiménez-Aguilar 1 , Marta Canela-Capdevila 3 , Raquel García-Pablo 2 , Helena Castañé 4 , Pablo Araguas 1 , Bárbara Malave 2 , Johana Cristina Acosta 2 , Rocío Benavides 2 , Miguel Árquez 2 , Fredy Castaño 2 , Francesc Riu 5 , Miriam de la Flor 6 , Coia Jordà 7 , Mireia Melé 2 , Jana Repkova 8 , Kepa Amillano 8 , Jordi Camps 9 , Jorge Joven 1 , Meritxell Arenas 2 1 Universitat Rovira i Virgili, Unitat de Recerca Biomèdica, Tarragona, Spain. 2 Hospital Universitari Sant Joan, Radiation Oncology, Reus, Spain. 3 Institut d'Investigació Sanitària Pere Virgili, Radiation Oncology, Reus, Spain. 4 Institut d'Investigació Sanitària Pere Virgili, Unitat de Recerca Biomèdica, Reus, Spain. 5 Hospital Universitari Sant Joan, Pathology, Reus, Spain. 6 Hospital Universitari Joan XXIII, Gynecology, Tarragona, Spain. 7 Hospital Universitari Sant Joan, Gynecology, Reus, Spain. 8 Hospital Universitari Sant Joan, Medical Oncology, Reus, Spain. 9 Hospital Universitari Sant Joan, Unitat de Recerca Biomèdica, Reus, Spain Breast cancer (BC) is a widespread solid tumor and a leading cause of cancer-related deaths among women globally. Metabolic reprogramming in BC is pivotal to its progression, contributing to distinct metabolomic profiles in various molecular subtypes. This study focuses on two key aspects: 1) Metabolomic Biomarkers in Response to BC Treatments: We explore the impact of surgical procedures, chemotherapy, and radiotherapy on BC patients, with a specific emphasis on investigating metabolomic changes in response to these treatments. 2)Metabolic Alterations in Peritumoral and Tumoral Tissue: Our study also examines metabolic differences in peritumoral and tumoral tissue in BC. We aim to discern unique metabolomic signatures at both tissue and systemic levels. By doing so, our objective is to uncover potential biomarkers and tissue associations that contribute to the onset and progression of the disease. Purpose/Objective:

Material/Methods:

77 female patients diagnosed with BC were recruited from two hospitals and a control group of 50 healthy women were included for comparison. The first treatment the patients received was surgery. Plasma samples were collected from BC patients after each treatment. Additionally, tissue samples were obtained from 13 of these patients. We performed semi-targeted metabolomics to explore metabolites associated with various metabolic pathways.

Results: